Indian pharma catching up to Ozempic, Mounjaro demand

The article highlights how Indian pharmaceutical companies are rapidly positioning themselves in the fast-growing global market for GLP-1 drugs, driven by demand for both diabetes and obesity treatments. However, it also notes that despite rising demand and innovation, significant disparities in access to diabetes care persist, particularly in low- and middle-income countries where insulin and essential treatments are often unaffordable or unavailable. 

Claudia Martínez, Director of Research at the Access to Medicine Foundation, is quoted as saying: “As the demand for GLP-1 medications continues to rise, it’s crucial that pharma companies don’t lose sight of the need to continue to invest in and develop affordable, accessible treatments for other critical diseases, especially those that hit the poorest countries hardest,” says Martinez of Access to Medicine Foundation.